Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 526

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 526
---
30, 2024, are summarized below (in thousands):

| Future Minimum Lease Payments:               |     |   |       |   |
|:---------------------------------------------|:----|:--|------:|:--|
| 2024                                         |     | $ |   130 |   |
| 2025                                         |     |   |   320 |   |
| 2026                                         |     |   |   231 |   |
| 2027                                         |     |   |   280 |   |
| 2028                                         |     |   |   109 |   |
| Total minimum lease payments                 |     | $ | 1,070 |   |
| Less: amount representing interest           |     |   |  (124 | ) |
| Present value of operating lease liabilities |     | $ |   946 |   |
| Less: operating lease liabilities, current   |     |   |  (322 | ) |
| Operating lease liabilities, non-current     |     | $ |   624 |   |
| Remaining lease term (in years)              |     |   |  3.33 |   |
| Incremental borrowing rate                   |     |   |  7.62 | % |

F-48

The Company includes the option to renew the lease as part of the right of use lease asset and liability
when it is reasonably certain the Company will exercise the option. In general, the Company is not reasonably certain to exercise such options.

7. License Agreements

Bristol Myers Squibb Company License Agreement

On April 9, 2014, the Company entered into a license agreement (as amended, the “BMS License Agreement”) with BMS for exclusive rights for
certain patents and a non-exclusive license for certain technology and know-how pertaining to FYARRO.

The BMS License Agreement will remain in effect from the effective date of April 9, 2014 until expiration of all milestone and royalty payment
obligations under the agreement, unless terminated by either of the parties upon giving advance notice as specified in the BMS License Agreement. Under the terms of the BMS License Agreement, BMS agreed to supply the Company with licensed products
of FYARRO necessary for clinical or non-clinical development.

Under the terms of the BMS License Agreement, BMS
is entitled to receive certain development milestone payments, royalties on net sales from licensed products under the agreement and any sublicense fees. During